EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Clinical development of allogeneic chimeric antigen receptor αβ-T cells

Christos Georgiadis, Roland Preece, Waseem Qasim

Molecular Therapy · 2025-06 · 33 (6) · 2426-2440

DOI: 10.1016/j.ymthe.2025.03.040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Therapy, 2025-06. Verfasst von Christos Georgiadis und 2 weiteren Autor:innen. Beteiligte Einrichtung: University College London Great Ormond Street Institute of Child Health, Zayed Centre for Research, 20 Guilford Street, London WC1N 1DZ, UK. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Receptors, Antigen, T-Cell, alpha-beta, Immunotherapy, Adoptive, T-Lymphocytes. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust, NIHR, UK Research and Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ready-made banks of allogeneic chimeric antigen receptor (CAR) T cells, produced to be available at the time of need, offer the prospect of accessible and cost-effective cellular therapies. Various strategies have been developed to overcome allogeneic barriers, drawing on cell engineering platforms including RNA interference, protein-based restriction, and genome editing, including RNA-guided CRISPR-Cas and base editing tools. Alloreactivity and the risk of graft-versus-host disease from non-matched donor cells have been mitigated by disruption of αβ-T cell receptor expression on the surface of T cells and stringent removal of any residual αβ-T cell populations. In addition, host-mediated rejection has been tackled through a combination of augmented lymphodepletion and cell engineering strategies that have allowed infused cells to evade immune recognition or conferred resistance to lymphodepleting agents to promote persistence and expansion of effector populations. Early-phase studies using off-the-shelf universal donor CAR T cells have been undertaken mainly in the context of blood malignancies, where emerging data of clinical responses have supported wider adoption and further applications. These developments offer the prospect of alternatives to current autologous approaches through the emerging application of genome engineering solutions to improve safety, persistence, and function of universal donor products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell, alpha-betaImmunotherapy, AdoptiveT-LymphocytesHumansGene EditingGraft vs Host DiseaseAnimalsTransplantation, Homologous

Stichwörter der Autor:innen

CRISPR-Cas9TALENSallogeneic cell therapybase editingchimeric antigen receptorcytidine deaminationgenome editing

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell, alpha-beta

Autor:innen und Institutionen

  • University College London Great Ormond Street Institute of Child Health, Zayed Centre for Research, 20 Guilford Street, London WC1N 1DZ, UK.
  • University College London Great Ormond Street Institute of Child Health, Zayed Centre for Research, 20 Guilford Street, London WC1N 1DZ, UK. Electronic address: w.qasim@ucl.ac.uk.

Förderung

  • Wellcome Trust
  • NIHR
  • UK Research and Innovation
  • UKRI MRC

Zitieren

APA

Georgiadis, C., Preece, R., & Qasim, W. (2025). Clinical development of allogeneic chimeric antigen receptor αβ-T cells. Molecular Therapy, 33(6), 2426-2440. https://doi.org/10.1016/j.ymthe.2025.03.040

Vancouver

Georgiadis C, Preece R, Qasim W. Clinical development of allogeneic chimeric antigen receptor αβ-T cells. Molecular Therapy. 2025;33(6):2426-2440. doi:10.1016/j.ymthe.2025.03.040

BibTeX
@article{Georgiadis2025,
  author = {Georgiadis, Christos and Preece, Roland and Qasim, Waseem},
  title = {Clinical development of allogeneic chimeric antigen receptor αβ-T cells},
  journal = {Molecular Therapy},
  year = {2025},
  volume = {33},
  number = {6},
  pages = {2426--2440},
  doi = {10.1016/j.ymthe.2025.03.040}
}
Kostenlos starten →